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ABSTRACT 
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two common forms of 
inflammatory bowel disease (IBD). They share similar clinical and demographic features as well 
as harbor key differences in tissue damage and prognosis. Previous studies indicated that they 
contributed to the increased rick to Colorectal cancer (CRC). However, whether UC and CD share 
inflammatory signatures still remains controversial. In addition, no inflammatory signatures have 
been reported on CRC. To answer these questions, a comprehensive study has been conducted on 
collected microarray datasets. Our analysis suggests that although CD and UC share common 
inflammatory pathways, they also present difference. Especially, CD patients are likely to have 
type I response, while UC patients are inclined to undergo type II response. Pathway enrichment 
analysis on CRC uncovered two potential CRC-specific inflammatory pathways.  
 
INDEX WORDS: Ulcerative colitis (UC), Crohn’s disease (CD), Inflammatory bowel disease 
(IBD), Colorectal cancer (CRC), Microarray, Pathway. 
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1 INTRODUCTION  
1.1 Inflammatory Bowel Disease (IBD) and Colorectal cancer (CRC) 
         Colorectal cancer (CRC) is the third most common cancer and the fourth most common 
cancer cause of death globally, accounting for roughly 1.2 million new cases and 600 000 deaths 
per year [1]. Many known factors such as genetic mutations, inflammatory bowel disease (IBD) 
can contribute to the occurrence of CRC. As the two common forms of IBD, both Ulcerative colitis 
(UC) and Crohn’s disease (CD) predispose patients to increased risk of CRC. A cohort study from 
Eaden et al reported that the probability of developing CRC 10 years after diagnosis of UC was 
2%, reaching the level of 8% after 20 years and 18% after 30 years [2]. A meta-analysis of 12 
published articles by Canavan et al showed that the cumulative risk for patients with Crohn’s 
disease (CD) was 2.9% at 10 years, 5.6% at 20 years, and 8.3% at 30 years after the CD diagnosis 
[3].  These studies indicated a comparable role of UC and CD in the cumulative risk of developing 
CRC. 
        Ulcerative colitis (UC) and Crohn’s disease (CD) share clinical and demographic features. 
However, they also harbor key differences in tissue damage and prognosis. UC is limited to the 
colon while CD can occur anywhere in the gastrointestinal tract. Inflammation in UC with crypt 
abscess formation is limited to the mucosa while a deeper, often transmural inflammation with 
fistula formation is seen in CD. All these different characteristics suggest distinctive 
etiopathogenic processes.  Wu, et al [4] and Lawrance, et al [5] have found different gene 
signatures between CD and UC diseases through microarray studies. Analysis of the mucosal T 
cell phenotype revealed that Th1 cells is predominant in CD disease, while Th2 cells is polarized 
in UC disease [6,7].  However, recent studies from Granlund, et. al showed that no Th preference 
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between CD and UC diseased [8]. These controversies intrigued us to re-evaluate these 
conclusions.  
     It was known that long-standing inflammation secondary to chronic infection or irritation can 
predispose to cancer [9]. The inverse is also true. Cancer can cause inflammation as smoldering, 
non-resolving inflammation is one of the consistent features of the tumor microenvironment [10]. 
Although some general features of cancer-related inflammation have been described, CRC-
specific inflammation signature has not been reported. Furthermore, it would be interesting to 
investigate the similarity and difference between IBD-associated inflammation signatures and 
CRC-associated ones. 
      Gene expression based technology has presented a high throughput tool in the field of cancer 
or diseased-related research. Since the advent of microarray, a large amounts of genome-wide gene 
expression data has been generated and collected in public archives. To date, the Gene Expression 
Omnibus (GEO), a repository of array- and sequence-based expression data, stores 1,947,791 
samples performed on 16,428 platforms [11]. However, in the case of same disease, analysis on 
microarrays submitted by different research groups will usually produce different results. Potential 
causes of this low reproducibility include differences in sample collection methods, processing 
protocols, and microarray platforms, patient heterogeneity, and analyzing algorithm or criteria 
[12]. Thus, studies based on a single batch microarray mostly lead to biased results. 
1.2 Expected Results  
      I would like to get the CD- and UC-common and unique inflammatory signatures. Meanwhile, 
through the CRC samples studies, we would be able to obtain the CRC-associated inflammatory 
signatures. Comparative analysis on these inflammatory signatures will inform us the similarity 
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and difference among them. These studies will further our understanding of the underling 
pathological mechanism of IBD and CRC.  
4 
2     METHODS 
2.1 Description of Data.  
        A thorough search of the Gene Expression Omnibus (GEO) results in five datasets that meets 
the following two criteria: (1), the deposited raw data are in CEL formats; (2), the datasets for IBD 
should contain both CD and UC samples. The raw data of the five datasets (GEO accession 
number: GSE6731 [4], GSE36807 [13], GSE4183 [14], GSE15960 [15], GSE37364 [16]) were 
downloaded from the at (http://www.ncbi.nlm.nih.gov/geo/). Detailed sample information on these 
microarrays are listed in Table.1, In total, our samples consist of 63 normal control (NM), 24 CD 
patients, 27 UC patients, and 48 CRC patients. 
 
Table 1. Data description of the five data set from GEO.  
GEO Ac.Nm NM CD UC CRC Ref 
GSE6731  4 6 5  Wu. et al., 2007 [4] 
GSE36807 7 12 13  Montero-Meléndez. et al., 
2013 [13] 
GSE4183 8 6 9 15 Galamb. et al, 2008 [14] 
GSE15960 6   6 Galamb. et al., 2010 [15] 
GSE37364 38   25 Valcz. et al., 2014 [16] 
Total 63 24 27 48  
 
2.2 Data processing and differential expression analysis 
         As is illustrated in Figure.1, raw data of these five datasets are separately imported into the 
R software by using the “affy” package [17], and separately processed by “vsn” package for 
variance stabilization, background correction, normalization and log transformation [18]. Through 
a non-specific filtration step using the “genefilter” package, we delete the redundant probes and 
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the ones lacking NCBI ENTRZID. In addition, this step also eliminates the probes whose variances 
are less than 0.5 [20]. This filtration process leaves us a total of 4298 genes in GSE6731 and a total 
of 10267 genes in the other four datasets to start with. By employing the “limma” package, 
differentially expressed genes were determined, these significantly differentially-expressed genes 
were further tested through the empirical Bayes method. Over-expressed genes are then selected 
based on the criteria with false discovery rate (FDR) ≤ 0.05 and fold changer ≥ 1.5 [21].  
 
 
Figure 1. Data processing and analysis pipeline 
2.3 Gene ontology over-representation analysis 
        Pathway over-representation analysis were performed using the “clusterProfiler” package, 
which uses Hypergeometric Testing to annotates genes to biological processes. To prevent high 
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false discovery rate (FDR), the Benjamini-Hochberg method (α = 0.05) is used in this process [22]. 
To decrease redundant GO terms, the annotated terms were further filtered at level four. Enriched 
GO terms are visualized using REVIGO at http://revigo.irb.hr/revigo.jsp [23]. Corresponding R 
code used for the above analysis was shown in appendix. A. 
2.4 Models and statistics  
        The “vsn” package introduces an additive-multiplicative error model for microarray gene 
expression data that comprises data calibration, quantification of differential expression, and 
quantification of measurement error. The package derives a transformation h for intensity 
measurements, in which the variance of the transformed intensities is independent of the mean. 
The parametric form is h(x)=arsinh(a+bx), where x stands for the probe intensity of each sample, 
while a and b are derived constant used for determining the mean of each probe intensity. These 
constants were well defined by Tibshiran R [18] and Huber et al [19]. In addition, a different 
statistic Δh, whose variance is approximately constant along the whole intensity range, is used to 
measure differential expression. For highly expressed genes, h coincides with the logarithmic 
transformation, and Δh with the log-ratio. All the parameters are estimated with a robust variant 
of maximum-likelihood estimation [19]. 
         In order to assess differentially expressed genes, the “limma” package fits a gene-wise linear 
models E[ yj ] = Xβj to gene expression data, where j stands for each gene, yj contains the 
expression data for the gene j, X is the design matrix and βj is a vector of coefficients which is 
interest. Here y 
  is the jth row of the expression matrix. The contrasts of interest are given by αj 
= CT βj where C is the contrasts matrix. The linear modelling is performed in a row-wise fashion, 
with regression coefficients and standard errors either directly estimating the comparisons of 
interest or via contrasts. Test-statistics are obtained for gene ranking that can be further 
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summarized at the gene set level to perform gene signature/pathway-level ranking. Additionally, 
the eBaye function of “limma” borrow information between genes when estimating the variances. 
It uses a robustified shrinkage strategy to estimate the gene-wise shrinkage factors, which offers 
the benefits of shrinkage to the majority of the genes, whilst negating the effects of outliers [21]. 
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3     RESULTS AND DISCUSSION 
3.1 CD and UC Show Different Gene Signatures 
       In Table.2, a total of 205 genes were found significantly alternated between the CD and NM 
groups, and 371 genes between the UC and NM groups in dataset GSE6731 according to the 
predefined criteria. Among these genes, 125 genes including 60 upregulated genes and 65 
downregulated genes were shared by CD and UC groups as was shown in Figure 2. In dataset 
GSE36807, a total of 186 genes were detected significantly expressed between the CD and NM 
groups, and 1196 genes between UC and NM groups. Among them, 57 upregulated genes and 99 
downregulated genes were shared between the CD and UC groups (Figure 2). More significantly 
differential expressed genes were discovered in dataset GSE4183. Between the CD and control 
groups, 1477 genes were detected significantly differentially expressed. This number was 1044 
between the UC and control groups. Among them, 580 upregulated and 185 downregulated genes 
were overlapped between the CD and UC groups (Figure.2). Due to batch effect, platform effect, 
and sample heterogeneity, the three datasets presented different number of significant genes. For 
the CD patients, 51.8% -83.8% of their differential expressed genes are shared by the UC patients. 
Clearly CD and UC patients displayed differential inflammatory signatures as well as similar ones 
at transcriptome level. 
3.2 Gene Signatures of CRC 
         Through the same procedure, we also obtained the gene signatures of CRC from the three 
datasets containing CRC patients. The three datasets gave various numbers of differentially 
expressed genes. As was shown in Table 2, Dataset GSE4183 gave the least number of 
differentially expressed genes (1180 genes) between CRC and normal groups, while dataset 
GSE15960 showed more differentially expressed genes (4412 genes) between the CRC and normal 
9 
groups. These difference are mainly caused by the high heterogeneity of the CRC patients, which 
has already indicated by Wu, et. al [4]. 
 
Table 2. Differentially expressed genes identified from each datasets. 
GEO Ac.Nm CD Vs NM UC Vs NM CRC Vs NM 
GSE6731  205 371  
GSE36807 186 1196  
GSE4183 1477 1003 1180 
GSE15960   4412 
GSE37364   2883 
 
 
Figure 2. Overlapped gene expression profiles between CD and UC groups 
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3.3 Pathway Enrichment Analysis on CD, UC, and CRC groups 
        The alteration of one gene can be attributed to different pathways due to the complexity of 
the gene regulation. Thus, analysis focused at the gene level usually failed to uncover the 
underlying biological mechanism. To investigate whether the CD and UC groups show different 
inflammatory signatures at higher level, we performed pathway over-representation analysis based 
on these differentially expressed genes by using the “clusterProfiler” package. Enriched pathways 
from each dataset are shown in Table 3. In the CD and the CRC groups, we could not find any 
conserved pathways from the three datasets. In the UC group, 2 pathways (GO:0019725, 
GO:0050921) are found conserved across the three datasets. A combination of all the pathways 
enriched from different datasets, we achieved a total of 195 CD-associated pathways and 196 UC-
associated pathways (Table 3). Similarly, pathway enrichment based on the differentially 
expressed genes from CRC datasets produced 149 CRC-associated pathways. An overview of 
these enriched pathways for different disease groups are shown in Figure 3. 
 
Table 3. Pathways enriched in different groups. 
GEO Ac.Nm CD UC CRC 
GSE6731  39 4  
GSE36807 3 138  
GSE4183 178 157 109 
GSE15960   2 
GSE15960   107 
    
Conserved 0 2       0 
Total 195 196 149 
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Figure 3. Interactive pathways enriched for CD, UC, and CRC diseases. 
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3.4 Comparative Analysis of Enriched Pathways from CD, UC and CRC 
         Comparative analysis of these CD- and UC-associated pathways indicated that 141 pathways 
were shared between CD and UC groups (listed in Table 6S). As we can see, some of these 
pathways such as GO:0002285, GO:0072676, GO:0019884, GO:0048002, GO:0002286, 
GO:0070489, GO:0070489, and so on, are directly associated with adaptive immune response, 
while complement activation (GO:0006956), and Toll-like receptor mediated signaling pathways 
(GO:0034122 and GO:0051092) signify the involvement of innate immune system. In addition, 
several enriched pathways (GO:0043299, GO:0097529, GO:0002274) are clearly indicative of the 
participation of myeloid cells in the inflammation response of IBD. These observations on the 
shared inflammatory signatures between CD and UC groups are consistent with those from 
Granlund, et. al [8].  
         It was known that Th1 cells secrete interleukin (IL)-2, interferon-γ, and lymphotoxin-α and 
stimulate type 1 immunity, which is characterized by intense phagocytic activity. Conversely, Th2 
cells secrete IL-4, IL-5, IL-9, IL-10, and IL-13 and stimulate type 2 immunity, which is 
accompanied by high antibody titers [24]. Interestingly, through analyzing the enriched CD-unique 
and UC-unique pathways, we also found that the CD and UC groups present different 
inflammatory features. As was seen in Table 4, the CD-unique immune-related pathways are 
characteristics of type I immune response as cell killing and oxidative burst are the features of 
phagocytic activity. On the contrary, type II immune response predominates in UC group. 
 
Table 4. Different inflammatory features of CD and UC patients. 
CD-unique immune-related pathways 
GO ID Description 
GO:001912 positive regulation of leukocyte mediated cytotoxicity 
13 
GO:0031341 regulation of cell killing 
GO:0001910 regulation of leukocyte mediated cytotoxicity 
GO:0002367 cytokine production involved in immune response 
GO:0045730 respiratory burst 
GO:0050776 regulation of immune response 
GO:0002577 regulation of antigen processing and presentation 
 
UC-unique immune-related pathways 
GO:0042092 type 2 immune response 
GO:0002279 mast cell activation involved in immune response 
GO:0002377 immunoglobulin production 
GO:0002532 
production of molecular mediator involved in 
inflammatory response 
GO:0002702 
positive regulation of production of molecular 
mediator of immune response 
GO:0019883 
antigen processing and presentation of endogenous 
antigen 
 
        Through a similar procedure, in total, 149 CRC-associated pathways (Table 7S) are obtained. 
As are expected, most of these pathways are the contributors of cancer growth and metastasis. For 
example, multiple pathways from CRC directly regulate the extracellular matrix such as 
GO:0033628, GO:0045785, GO:0031589, GO:0030155, GO:0033627, and so on. Various 
pathways such as GO:0051321, GO:0051781, GO:0051445, GO:0051302, GO:1903046, 
GO:0090068, GO:0007126, GO:0051301, GO:0010564 are closely related to the cell proliferation 
processes. Additionally, several pathways such as GO:2000146, GO:2000147, GO:0050921, 
GO:0010632 clearly regulate cell migration.   
        Among the 149 CRC-associated pathways, 68 of them were shared with the CD group and 
77 of them were shared with the UC group (Figure 3 and Table 7S). Interestingly, 60 pathways are 
found across the three groups. Among these pathways, 10 of them are inflammation-related such 
as GO:0002443, GO:0002250, GO:0071674, GO:0009617, GO:0006959, GO:0009611, GO:0002687, 
14 
GO:0097529, GO:0006956, GO:0030595, which indicates that CRC shares inflammatory features with CD 
and UC diseases.  In addition, pathways, for example, GO:1901343, GO:1904018, GO:0008285, 
GO:0045785, GO:0050673, GO:0030155, and GO:0043062, are extracellular matrix-related or cell 
proliferation-related, suggesting that CRC and IBD also employ similar mechanism to remodel local 
tissues and regulate the cells which are involved in these biological process.  
 
Figure 4. Shared pathways among different diseases. 
 
          
       Analysis on the 64 CRC-unique pathways showed that 31 of these pathways are cell-cycle-
regulation- or cell metabolism-related, implying that that CRC are distinct from IBD in their cell 
regulating mechanism.  Further analysis also uncovered two GO pathways for potential CRC-
specific inflammation-related pathways (Table.5). 
Table 5. Two Candidate GO Pathways for CRC-related Inflammation. 
GO ID Description 
GO:0098869 cellular oxidant detoxification  
GO:0002686 negative regulation of leukocyte migration 
 
15 
4 CONCLUSIONS 
     In this study, a comprehensive analysis was conducted on CD, UC and CRC at gene and 
pathway level. According to our knowledge, this is the most comprehensive studies on these three 
forms of diseases. Our studies indicated that CD and UC present different gene signatures at 
transcriptome level, which is consistent with the studies from Wu, et al [4] and Lawrance, et al [5]. 
Furthermore, our over-representation pathway analysis on these differentially expressed genes 
revealed that 72% (141/195) of these pathways are shared between CD and UC diseases, including 
various immune-related pathways. However, they also show different inflammatory features. 
Especially, type I immune response predominate in CD disease, while type II immune response 
are more favored in UC diseases. On this point, our results are different from Granlund, et. al [8]. 
In their studies, they could not detect any signs of Th2 differentiation, while our pathway analysis 
clearly shows Th2 response in UC patients. Two reasons might cause this difference. On one side, 
Granlund, et. al’s analysis are mainly focused at gene level, the characteristic Th2 gene signatures 
might not significantly show up in their sample or be detected by their analyzing criteria. On the 
other side, although they have conducted gene set enrichment analysis, their pathway analysis is 
enriched at more general level. These reasons possibly mask the difference between CD and UC 
groups.  
     Pathway enrichment on the panel of selected genes from CRC uncovered 149 potential 
pathways. Analyzing these pathways found that CRC shares inflammatory features with IBD 
diseases and remodels local tissues and regulate involved cells through a similar mechanism. A 
comparison of CRC-associated pathways with CD- and UC-associated pathways revealed 64 
CRC-specific pathways. Further investigation of these CRC-specific pathways indicated that CRC 
are different from IBD in their cell regulating mechanism. In addition to these, two pathways are 
16 
uncovered to be potential candidates for the CRC-associated inflammation. It would be interesting 
to apply these finding on CRC patients in the TCGA database. 
     In summary, by using publicly available data sets, the present studies for the first time point out 
the Th preference of CD and UC patients, which are consistent with previous experiment data. 
Furthermore, our studies also unmask the similarity and distinction between CRC and IBD 
diseases, which furthered our understanding of the pathogenesis of these disease.  
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APPENDICES  
Appendix A 
# load the required R pacakages; 
library("Biobase") 
library("annotate") 
library("hgu133plus2.db") 
library("hgu133plus2.db") 
library("hgu95av2.db") 
library(limma)  
library(genefilter) 
library("affy") 
library("vsn") 
library("clusterProfiler") 
 
#setup data directory and read data into R; 
setwd("C:/Users/little-Z/Desktop/thesis data/GSExxxxxx_CEL") 
getwd() 
Data=ReadAffy() 
#do background calculation, normalization, log2 transformation, rename sample names, 
checking fitting; 
geset=vsnrma(Data) 
meanSdPlot(geset) 
sampleNames(geset) = substr(sampleNames(geset),1,9) 
21 
sampleNames(geset) 
#check the normality of the samples; 
boxplot(exprs(geset)) 
#non-specific filtration to remove control probes and probes which have no entrez ID, are 
redundant; 
qrange <- function(x) diff(quantile(x, c(0.1, 0.9))) 
filt_geset = nsFilter(geset, require.entrez=TRUE, remove.dupEntrez=TRUE, var.func=qrange, 
var.cutoff=0.5, feature.exclude="^AFFX") 
#construct matrix for model fitting and linear model fitting 
group=as.factor(c(rep("NM",a), rep("CD",b), rep("UC",c), rep("CRC",d))); # a, b, c, d, are the 
number of samples of NM, CD, UC, CRC; 
v = filt_geset$eset 
design=model.matrix(~0+group) 
colnames(design)=gsub("group", "", colnames(design)) 
design 
contr.matrix=makeContrasts(CDvsNM=CD-NM, UCvsNM=UC-NM, CRCvsNM=CRC-NM, 
levels = colnames(design)) 
contr.matrix 
vft=lmFit(v, design) 
vft=contrasts.fit(vft, contrasts=contr.matrix) 
# empirical bayes moderation; 
eft=eBayes(vft) 
plotSA(eft) 
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#select differentially expressed genes; 
dt=decideTests(eft,adjust.method="BH",p.value=0.05,lfc=0.585) 
summary(dt) 
# vennDiagram shows the overlapping genes; 
vennDiagram(dt[,1:2], include = c("up", "down"),counts.col=c("red", 
"blue"),circle.col=c("turquoise", "salmon")) 
#extract differentially expressed genes for UC, CD, and CRC group. 
Syms = unlist(mget(featureNames(v), env = hgu133plus2ENTREZID)) 
top1=topTable(eft, coef = 1, adjust.method = "fdr",sort.by = "p", number=Inf, genelist = Syms) 
top11=top1[abs(top1$logFC)>=0.585 & top1$adj.P.Val<=0.05,] 
dim(top11) 
top2=topTable(eft, coef = 2, adjust.method = "fdr",sort.by = "p", number=Inf, genelist = Syms) 
top22=top2[abs(top2$logFC)>=0.585 & top2$adj.P.Val<=0.05,] 
dim(top22) 
top3= topTable(eft, coef = 3, adjust.method = "fdr",sort.by = "p", number=Inf, genelist = Syms) 
top33=top3[abs(top3$logFC)>=0.585 & top3$adj.P.Val<=0.05,] 
dim(top33) 
# pathway enrichment using differentially expressed genes from CD, UC, and CRC group; 
Gene=top11$ID 
Pathway= enrichGO(gene= GSE_UC_4183$ID, 
                universe      = TOT, 
                OrgDb         = org.Hs.eg.db, 
                ont           = "BP", 
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                pAdjustMethod = "BH", 
                pvalueCutoff  = 0.05, 
                qvalueCutoff  = 0.05, 
                readable      = TRUE) 
summary(x) 
L4_path=gofilter(Pathway,level=4) 
#produce the Ven diagram of overlapped pathways; 
set1=as.character(CD_total_path_order$ID) 
set2=as.character(UC_total_path_order$ID) 
set3=as.character(CRC_total_path_order$ID) 
universe =sort(unique(c(set1, set2, set3))) 
Counts =matrix(0, nrow=length(universe), ncol=3) 
for (i in 1:length(universe)) { 
    Counts[i,1] <- universe[i] %in% set1 
    Counts[i,2] <- universe[i] %in% set2 
    Counts[i,3] <- universe[i] %in% set3 
} 
colnames(Counts) <- c("CD","UC","CRC") 
cols<-c("Red", "Green", "Blue") 
 vennDiagram(vennCounts(Counts), circle.col=cols) 
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Appendix B 
Table 6S. Enriched CD- and UC- shared and -specific pathways 
Enriched CD and UC shared pathways  
ID Description pvalue p.adjust GeneRatio 
GO:0051283 negative regulation of sequestering of calcium 
ion 
0.007174 0.045861 17/1408 
GO:0034122 negative regulation of toll-like receptor 
signaling pathway 
0.006952 0.044649 7/1408 
GO:0051092 positive regulation of NF-kappaB transcription 
factor activity 
0.006207 0.041039 22/1408 
GO:0090130 tissue migration 0.005905 0.039598 39/1408 
GO:0033627 cell adhesion mediated by integrin 0.00547 0.037243 14/1408 
GO:0010876 lipid localization 0.004976 0.035086 48/1408 
GO:0048729 tissue morphogenesis 0.004962 0.035051 85/1408 
GO:0051701 interaction with host 0.004905 0.034876 30/1408 
GO:0032102 negative regulation of response to external 
stimulus 
0.004545 0.032753 36/1408 
GO:2000242 negative regulation of reproductive process 0.00399 0.029702 11/1408 
GO:0051282 regulation of sequestering of calcium ion 0.003592 0.027322 18/1408 
GO:0072676 lymphocyte migration 0.003259 0.025336 17/1408 
GO:0032409 regulation of transporter activity 0.003197 0.025252 27/1408 
GO:0043299 leukocyte degranulation 0.003148 0.024975 15/1408 
GO:0010524 positive regulation of calcium ion transport into 
cytosol 
0.002867 0.023313 10/1408 
GO:0055086 nucleobase-containing small molecule 
metabolic process 
0.002747 0.023047 91/1408 
GO:0002701 negative regulation of production of molecular 
mediator of immune response 
0.002652 0.022335 9/1408 
GO:0001666 response to hypoxia 0.002359 0.020433 46/1408 
GO:0032845 negative regulation of homeostatic process 0.002115 0.018901 29/1408 
GO:0050920 regulation of chemotaxis 0.002102 0.047495 11/201 
GO:2001057 reactive nitrogen species metabolic process 0.002074 0.047495 7/201 
GO:0051235 maintenance of location 0.002012 0.018168 43/1408 
GO:0050673 epithelial cell proliferation 0.001962 0.017834 53/1408 
GO:0006935 chemotaxis 0.001748 0.043283 20/201 
GO:0042330 taxis 0.001748 0.043283 20/201 
GO:0042493 response to drug 0.001744 0.016163 60/1408 
GO:0048525 negative regulation of viral process 0.00173 0.016102 21/1408 
GO:0043900 regulation of multi-organism process 0.001697 0.043001 17/201 
GO:1903708 positive regulation of hemopoiesis 0.001595 0.01515 30/1408 
GO:0001816 cytokine production 0.001548 0.039984 24/201 
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GO:0009620 response to fungus 0.001492 0.014463 11/1408 
GO:0042267 natural killer cell mediated cytotoxicity 0.001492 0.014463 11/1408 
GO:0050778 positive regulation of immune response 0.001486 0.038748 27/201 
GO:0010522 regulation of calcium ion transport into cytosol 0.001396 0.013875 16/1408 
GO:1903530 regulation of secretion by cell 0.001243 0.012627 77/1408 
GO:0002443 leukocyte mediated immunity 0.00116 0.034581 15/201 
GO:0001763 morphogenesis of a branching structure 0.001123 0.011652 36/1408 
GO:0010035 response to inorganic substance 0.001112 0.011625 68/1408 
GO:0007584 response to nutrient 0.001056 0.011125 32/1408 
GO:0035295 tube development 0.000989 0.01058 83/1408 
GO:1904951 positive regulation of establishment of protein 
localization 
0.000987 0.01058 74/1408 
GO:0070482 response to oxygen levels 0.000879 0.00982 51/1408 
GO:0070489 T cell aggregation 0.00087 0.02809 20/201 
GO:0071559 response to transforming growth factor beta 0.000862 0.009682 38/1408 
GO:0044253 positive regulation of multicellular organismal 
metabolic process 
0.000855 0.009625 7/1408 
GO:0070168 negative regulation of biomineral tissue 
development 
0.000855 0.009625 7/1408 
GO:1903524 positive regulation of blood circulation 0.000817 0.009422 16/1408 
GO:0019725* cellular homeostasis 0.000762 0.025514 27/201 
GO:0010243 response to organonitrogen compound 0.000755 0.025514 28/201 
GO:2000257 regulation of protein activation cascade 0.000745 0.025514 5/201 
GO:0002507 tolerance induction 0.000683 0.00817 9/1408 
GO:0008285 negative regulation of cell proliferation 0.000677 0.024266 25/201 
GO:0019884 antigen processing and presentation of 
exogenous antigen 
0.000616 0.023428 13/201 
GO:0071674 mononuclear cell migration 0.000571 0.007086 18/1408 
GO:0032844 regulation of homeostatic process 0.000462 0.005946 65/1408 
GO:0003254 regulation of membrane depolarization 0.000449 0.005803 11/1408 
GO:0001101 response to acid chemical 0.000449 0.005803 45/1408 
GO:0044364 disruption of cells of other organism 0.000429 0.005751 8/1408 
GO:0001503 ossification 0.000392 0.005413 58/1408 
GO:0048534 hematopoietic or lymphoid organ development 0.00034 0.004803 106/1408 
GO:0006959 humoral immune response 0.000332 0.015284 11/201 
GO:1901343 negative regulation of vasculature development 0.00033 0.004726 18/1408 
GO:0002250 adaptive immune response 0.000253 0.013101 17/201 
GO:0043270 positive regulation of ion transport 0.000249 0.003741 33/1408 
GO:0060761 negative regulation of response to cytokine 
stimulus 
0.000228 0.003513 12/1408 
GO:1904018 positive regulation of vasculature development 0.000222 0.003454 29/1408 
GO:0002700 regulation of production of molecular mediator 
of immune response 
0.000198 0.003188 23/1408 
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GO:0048002 antigen processing and presentation of peptide 
antigen 
0.000193 0.011356 14/201 
GO:2000146 negative regulation of cell motility 0.000189 0.003083 43/1408 
GO:0002285 lymphocyte activation involved in immune 
response 
0.000164 0.00277 30/1408 
GO:0006956 complement activation 0.00012 0.002112 16/1408 
GO:0050817 coagulation 0.00012 0.002109 56/1408 
GO:1903706 regulation of hemopoiesis 0.000105 0.001864 54/1408 
GO:0007586 digestion 0.0001 0.047432 8/165 
GO:0040013 negative regulation of locomotion 9.72E-05 0.001748 47/1408 
GO:0016337 single organismal cell-cell adhesion 7.19E-05 0.00542 30/201 
GO:0008360 regulation of cell shape 6.47E-05 0.001272 31/1408 
GO:0009615 response to virus 6.41E-05 0.005212 18/201 
GO:0051093 negative regulation of developmental process 5.96E-05 0.001186 108/1408 
GO:0050878 regulation of body fluid levels 5.54E-05 0.001125 72/1408 
GO:0051271 negative regulation of cellular component 
movement 
5.42E-05 0.001109 48/1408 
GO:0060759 regulation of response to cytokine stimulus 4.92E-05 0.001023 29/1408 
GO:0072593 reactive oxygen species metabolic process 4.15E-05 0.000875 45/1408 
GO:0002218 activation of innate immune response 4.08E-05 0.000867 49/1408 
GO:0002286 T cell activation involved in immune response 3.95E-05 0.000842 21/1408 
GO:0002523 leukocyte migration involved in inflammatory 
response 
3.67E-05 0.000791 8/1408 
GO:0032103 positive regulation of response to external 
stimulus 
2.74E-05 0.002757 18/201 
GO:2000021 regulation of ion homeostasis 2.07E-05 0.000483 34/1408 
GO:0051607 defense response to virus 1.98E-05 0.002097 15/201 
GO:0050921* positive regulation of chemotaxis 1.75E-05 0.00041 30/1408 
GO:0032101 regulation of response to external stimulus 1.72E-05 0.001948 30/201 
GO:0007565 female pregnancy 1.66E-05 0.000395 34/1408 
GO:0048771 tissue remodeling 1.53E-05 0.000368 32/1408 
GO:0001818 negative regulation of cytokine production 1.43E-05 0.000347 40/1408 
GO:0097529 myeloid leukocyte migration 1.32E-05 0.001632 14/201 
GO:0030595 leukocyte chemotaxis 1.20E-05 0.00163 16/201 
GO:0044057 regulation of system process 1.06E-05 0.000269 63/1408 
GO:0002699 positive regulation of immune effector process 1.05E-05 0.000269 34/1408 
GO:0043901 negative regulation of multi-organism process 9.98E-06 0.00026 31/1408 
GO:0009617 response to bacterium 7.94E-06 0.001197 25/201 
GO:0071216 cellular response to biotic stimulus 2.24E-06 6.55E-05 39/1408 
GO:0045123 cellular extravasation 1.25E-06 3.83E-05 19/1408 
GO:0007162 negative regulation of cell adhesion 1.03E-06 3.20E-05 48/1408 
GO:0098542 defense response to other organism 8.04E-07 0.000241 23/201 
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GO:0002757 immune response-activating signal 
transduction 
7.62E-07 2.43E-05 82/1408 
GO:0009611 response to wounding 4.88E-07 1.62E-05 103/1408 
GO:0002698 negative regulation of immune effector process 4.53E-07 1.51E-05 27/1408 
GO:0002274 myeloid leukocyte activation 4.18E-07 1.41E-05 37/1408 
GO:0002366 leukocyte activation involved in immune 
response 
2.40E-07 8.48E-06 47/1408 
GO:0002696 positive regulation of leukocyte activation 2.00E-07 7.24E-06 60/1408 
GO:0001819 positive regulation of cytokine production 1.95E-07 7.15E-06 71/1408 
GO:0002263 cell activation involved in immune response 1.10E-07 4.24E-06 48/1408 
GO:0050866 negative regulation of cell activation 9.79E-08 3.81E-06 38/1408 
GO:0045087 innate immune response 9.12E-08 4.00E-05 40/201 
GO:0002687 positive regulation of leukocyte migration 9.09E-08 3.57E-06 34/1408 
GO:0031349 positive regulation of defense response 7.88E-08 3.16E-06 77/1408 
GO:0043207 response to external biotic stimulus 4.40E-08 2.39E-05 39/201 
GO:0050867 positive regulation of cell activation 2.69E-08 1.16E-06 64/1408 
GO:0002695 negative regulation of leukocyte activation 1.86E-08 8.23E-07 36/1408 
GO:2000147 positive regulation of cell motility 8.98E-09 4.38E-07 85/1408 
GO:0040017 positive regulation of locomotion 7.94E-09 3.97E-07 86/1408 
GO:0048514 blood vessel morphogenesis 7.28E-09 3.68E-07 97/1408 
GO:0003013 circulatory system process 5.90E-09 3.17E-07 78/1408 
GO:0002685 regulation of leukocyte migration 4.86E-09 2.65E-07 44/1408 
GO:0044236 multicellular organism metabolic process 4.85E-09 2.65E-07 37/1408 
GO:0022409 positive regulation of cell-cell adhesion 4.45E-09 2.52E-07 56/1408 
GO:0051272 positive regulation of cellular component 
movement 
2.61E-09 1.56E-07 88/1408 
GO:0001525 angiogenesis 1.83E-09 1.19E-07 88/1408 
GO:0001568 blood vessel development 1.57E-09 1.06E-07 111/1408 
GO:0002694 regulation of leukocyte activation 8.25E-10 6.14E-08 87/1408 
GO:0046649 lymphocyte activation 5.58E-10 4.74E-08 113/1408 
GO:0045785 positive regulation of cell adhesion 3.01E-10 2.77E-08 80/1408 
GO:0070661 leukocyte proliferation 2.51E-10 2.42E-08 62/1408 
GO:0050865 regulation of cell activation 1.44E-10 1.42E-08 94/1408 
GO:0002697 regulation of immune effector process 6.15E-11 7.25E-09 69/1408 
GO:0022407 regulation of cell-cell adhesion 3.61E-11 4.81E-09 82/1408 
GO:0001817 regulation of cytokine production 2.55E-11 3.74E-09 107/1408 
GO:0050777 negative regulation of immune response 8.55E-12 1.34E-09 36/1408 
GO:0002683 negative regulation of immune system process 3.42E-13 8.07E-11 84/1408 
GO:0030155 regulation of cell adhesion 1.41E-14 4.61E-12 132/1408 
GO:0043062 extracellular structure organization 1.02E-14 3.59E-12 85/1408 
Enriched CD-specific pathways  
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GO:0060135 maternal process involved in female pregnancy 0.007553 0.04715 13/1408 
GO:0001912 positive regulation of leukocyte mediated 
cytotoxicity 
0.007514 0.04715 8/1408 
GO:0051047 positive regulation of secretion 0.007435 0.047035 47/1408 
GO:0035637 multicellular organismal signaling 0.00709 0.045466 21/1408 
GO:0002577 regulation of antigen processing and 
presentation 
0.006952 0.044649 7/1408 
GO:0060711 labyrinthine layer development 0.006516 0.042293 12/1408 
GO:0048732 gland development 0.006342 0.041548 58/1408 
GO:0048565 digestive tract development 0.006323 0.041548 23/1408 
GO:0031589 cell-substrate adhesion 0.00599 0.039962 48/1408 
GO:0060348 bone development 0.004905 0.034876 30/1408 
GO:0035239 tube morphogenesis 0.004597 0.033078 53/1408 
GO:0032835 glomerulus development 0.00434 0.03155 14/1408 
GO:0045596 negative regulation of cell differentiation 0.003991 0.029702 77/1408 
GO:0032846 positive regulation of homeostatic process 0.00372 0.028099 33/1408 
GO:0032411 positive regulation of transporter activity 0.003407 0.026347 14/1408 
GO:0032970 regulation of actin filament-based process 0.003281 0.02546 49/1408 
GO:0090288 negative regulation of cellular response to 
growth factor stimulus 
0.002842 0.023313 23/1408 
GO:0034104 negative regulation of tissue remodeling 0.002777 0.023069 7/1408 
GO:0098901 regulation of cardiac muscle cell action potential 0.002777 0.023069 7/1408 
GO:0035383 thioester metabolic process 0.002632 0.02232 19/1408 
GO:0030278 regulation of ossification 0.002517 0.021719 32/1408 
GO:0045648 positive regulation of erythrocyte differentiation 0.002241 0.019538 8/1408 
GO:0090066 regulation of anatomical structure size 0.002185 0.01928 64/1408 
GO:0008217 regulation of blood pressure 0.001946 0.017725 26/1408 
GO:0003012 muscle system process 0.001593 0.01515 49/1408 
GO:0051781 positive regulation of cell division 0.001579 0.040389 6/201 
GO:0031341 regulation of cell killing 0.001568 0.014988 13/1408 
GO:0045646 regulation of erythrocyte differentiation 0.001492 0.014463 11/1408 
GO:0034103 regulation of tissue remodeling 0.001475 0.014463 15/1408 
GO:0051270 regulation of cellular component movement 0.00122 0.035737 29/201 
GO:0002504 antigen processing and presentation of peptide 
or polysaccharide antigen via MHC class II 
0.001096 0.033383 8/201 
GO:0042391 regulation of membrane potential 0.000992 0.010586 40/1408 
GO:0051222 positive regulation of protein transport 0.000987 0.01058 66/1408 
GO:0098900 regulation of action potential 0.000887 0.009827 10/1408 
GO:0090287 regulation of cellular response to growth factor 
stimulus 
0.000657 0.007971 39/1408 
GO:0098609 cell-cell adhesion 0.000631 0.023428 39/201 
GO:0001910 regulation of leukocyte mediated cytotoxicity 0.000582 0.007184 13/1408 
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GO:0001775 cell activation 0.000501 0.019403 33/201 
GO:1901698 response to nitrogen compound 0.000477 0.018752 31/201 
GO:0002367 cytokine production involved in immune 
response 
0.000417 0.005654 19/1408 
GO:0016477 cell migration 0.000368 0.016371 41/201 
GO:0045730 respiratory burst 0.000342 0.004803 10/1408 
GO:0002027 regulation of heart rate 0.000247 0.003728 17/1408 
GO:0030029 actin filament-based process 0.000235 0.003603 92/1408 
GO:0045124 regulation of bone resorption 0.000143 0.002442 12/1408 
GO:0002684 positive regulation of immune system process 0.000131 0.009036 38/201 
GO:0031348 negative regulation of defense response 0.000106 0.001868 28/1408 
GO:0034764 positive regulation of transmembrane transport 9.17E-05 0.001686 23/1408 
GO:0098602 single organism cell adhesion 6.73E-05 0.005212 32/201 
GO:0008284 positive regulation of cell proliferation 6.56E-05 0.005212 31/201 
GO:0050776 regulation of immune response 6.50E-05 0.005212 36/201 
GO:0031016 pancreas development 2.37E-05 0.020337 7/165 
GO:0034330 cell junction organization 2.15E-05 0.000496 49/1408 
GO:0031018 endocrine pancreas development 1.41E-05 0.020337 6/165 
Enriched UC-specific pathways  
GO:1900076 regulation of cellular response to insulin 
stimulus 
0.006513 0.049867 11/1093 
GO:0008037 cell recognition 0.006261 0.048376 16/1093 
GO:0042092 type 2 immune response 0.006257 0.043929 7/917 
GO:0044246 regulation of multicellular organismal metabolic 
process 
0.006257 0.043929 7/917 
GO:0045912 negative regulation of carbohydrate metabolic 
process 
0.006257 0.043929 7/917 
GO:0044703 multi-organism reproductive process 0.006133 0.047508 70/1093 
GO:0007588 excretion 0.005713 0.045648 9/1093 
GO:1990267 response to transition metal nanoparticle 0.005545 0.045046 19/1093 
GO:0030324 lung development 0.004891 0.041272 25/1093 
GO:0061383 trabecula morphogenesis 0.004601 0.035421 10/917 
GO:0035966 response to topologically incorrect protein 0.004556 0.038829 27/1093 
GO:0007566 embryo implantation 0.004543 0.035393 9/917 
GO:0010632 regulation of epithelial cell migration 0.004375 0.034477 22/917 
GO:0060760 positive regulation of response to cytokine 
stimulus 
0.004165 0.036683 8/1093 
GO:0030279 negative regulation of ossification 0.00401 0.036146 12/1093 
GO:0001704 formation of primary germ layer 0.003652 0.033938 19/1093 
GO:0009268 response to pH 0.003572 0.033417 7/1093 
GO:0060713 labyrinthine layer morphogenesis 0.003572 0.033417 7/1093 
GO:0005975 carbohydrate metabolic process 0.003102 0.030649 59/1093 
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GO:0002702 positive regulation of production of molecular 
mediator of immune response 
0.003072 0.026092 11/917 
GO:0048871 multicellular organismal homeostasis 0.003037 0.030078 36/1093 
GO:0009612 response to mechanical stimulus 0.003004 0.030032 26/1093 
GO:0019883 antigen processing and presentation of 
endogenous antigen 
0.002942 0.025093 5/917 
GO:0045454 cell redox homeostasis 0.002871 0.024852 13/917 
GO:0007568 aging 0.002637 0.027203 35/1093 
GO:0002643 regulation of tolerance induction 0.002518 0.026232 6/1093 
GO:0030195 negative regulation of blood coagulation 0.002492 0.026146 9/1093 
GO:1900047 negative regulation of hemostasis 0.002492 0.026146 9/1093 
GO:0051048 negative regulation of secretion 0.002405 0.025693 25/1093 
GO:0002279 mast cell activation involved in immune 
response 
0.002226 0.020262 9/917 
GO:0002532 production of molecular mediator involved in 
inflammatory response 
0.002226 0.020262 9/917 
GO:0048286 lung alveolus development 0.002006 0.022386 10/1093 
GO:2000241 regulation of reproductive process 0.001894 0.02166 18/1093 
GO:0051051 negative regulation of transport 0.00181 0.021065 50/1093 
GO:0006949 syncytium formation 0.001349 0.013527 8/917 
GO:0050819 negative regulation of coagulation 0.001099 0.014717 10/1093 
GO:0051238 sequestering of metal ion 0.000981 0.010371 17/917 
GO:0009991 response to extracellular stimulus 0.000959 0.013862 51/1093 
GO:1901615 organic hydroxy compound metabolic process 0.000922 0.013486 45/1093 
GO:0010942 positive regulation of cell death 0.000899 0.013416 72/1093 
GO:0035821 modification of morphology or physiology of 
other organism 
0.000708 0.011104 19/1093 
GO:0040008 regulation of growth 0.000532 0.00912 69/1093 
GO:0010634 positive regulation of epithelial cell migration 0.000476 0.005884 18/917 
GO:0050792 regulation of viral process 0.000379 0.00698 39/1093 
GO:0022600 digestive system process 0.000282 0.00558 15/1093 
GO:1903409 reactive oxygen species biosynthetic process 0.000231 0.003343 16/917 
GO:0043903 regulation of symbiosis, encompassing 
mutualism through parasitism 
0.000156 0.003607 42/1093 
GO:0002377 immunoglobulin production 0.000102 0.001677 17/917 
GO:1903036 positive regulation of response to wounding 6.27E-05 0.001674 13/1093 
GO:0050820 positive regulation of coagulation 5.35E-05 0.001485 9/1093 
GO:0030194 positive regulation of blood coagulation 2.82E-05 0.000918 9/1093 
GO:1900048 positive regulation of hemostasis 2.82E-05 0.000918 9/1093 
GO:0030193 regulation of blood coagulation 9.33E-06 0.000428 19/1093 
GO:1900046 regulation of hemostasis 9.33E-06 0.000428 19/1093 
GO:0050818 regulation of coagulation 5.72E-06 0.000306 20/1093 
*: indicating the two conserved pathways in UC group. 
31 
Appendix C 
Table 7S. Enriched pathways for CRC. 
 
ID Description pvalue p.adjust GeneRatio 
GO:0007062 sister chromatid cohesion 0.004055 0.048549 22/1114 
GO:0021549 cerebellum development 0.003799 0.047023 12/1114 
GO:2000257*# regulation of protein activation cascade 0.003777 0.04797 Dec-18 
GO:0051781*# positive regulation of cell division 0.003599 0.045346 13/1114 
GO:0048732* gland development 0.003583 0.045346 49/1114 
GO:0072593*# reactive oxygen species metabolic process 0.003499 0.045865 63/2618 
GO:0045992 negative regulation of embryonic development 0.003424 0.044295 8/1114 
GO:0051983 regulation of chromosome segregation 0.003387 0.044084 16/1114 
GO:0030902 hindbrain development 0.00324 0.042554 18/1114 
GO:0051321 meiotic cell cycle 0.003115 0.041651 25/1114 
GO:0051445 regulation of meiotic cell cycle 0.003114 0.041915 13/2618 
GO:0050818# regulation of coagulation 0.003106 0.041651 15/1114 
GO:0030324# lung development 0.003083 0.041651 26/1114 
GO:0001822 kidney development 0.003065 0.041685 71/2618 
GO:0030850 prostate gland development 0.003049 0.041555 10/1114 
GO:0022600# digestive system process 0.003045 0.041685 23/2618 
GO:1990267# response to transition metal nanoparticle 0.002975 0.040923 37/2618 
GO:0007507 heart development 0.002837 0.039279 56/1114 
GO:0030728* ovulation 0.00278 0.038624 6/1114 
GO:0001942 hair follicle development 0.00278 0.039079 25/2618 
GO:0022404 molting cycle process 0.00278 0.039079 25/2618 
GO:0060348* bone development 0.002733 0.038462 26/1114 
GO:0045926 negative regulation of growth 0.002328 0.034689 58/2618 
GO:0043207*# response to external biotic stimulus 0.002283 0.033765 82/1114 
GO:1901343*# negative regulation of vasculature development 0.002256 0.033606 14/1114 
GO:0033002 muscle cell proliferation 0.00222 0.033985 47/2618 
GO:0022037 metencephalon development 0.002134 0.033306 23/2618 
GO:0051302 regulation of cell division 0.002117 0.032518 19/1114 
GO:0002686 negative regulation of leukocyte migration 0.002086 0.032173 9/1114 
GO:1903046 meiotic cell cycle process 0.002048 0.031814 22/1114 
GO:0090068 positive regulation of cell cycle process 0.002047 0.032335 62/2618 
GO:0098869 cellular oxidant detoxification 0.002032 0.032217 28/2618 
GO:0007126 meiotic nuclear division 0.001986 0.031066 21/1114 
GO:0002443*# leukocyte mediated immunity 0.001885 0.030633 72/2618 
GO:0010810 regulation of cell-substrate adhesion 0.001865 0.029492 28/1114 
GO:0045596* negative regulation of cell differentiation 0.001843 0.029256 65/1114 
GO:0009566 fertilization 0.001739 0.028548 15/1114 
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GO:0006730 one-carbon metabolic process 0.001731 0.029202 13/2618 
GO:0035036 sperm-egg recognition 0.001671 0.028173 6/1114 
GO:0007584*# response to nutrient 0.001583 0.027975 50/2618 
GO:0009994 oocyte differentiation 0.001497 0.025543 9/1114 
GO:0008608 attachment of spindle microtubules to 
kinetochore 
0.001452 0.026483 14/2618 
GO:0002250*# adaptive immune response 0.001424 0.026412 84/2618 
GO:0007566# embryo implantation 0.001416 0.024548 11/1114 
GO:0050803 regulation of synapse structure or activity 0.001389 0.02606 25/2618 
GO:0048771*# tissue remodeling 0.001361 0.023826 23/1114 
GO:0051222* positive regulation of protein transport 0.001324 0.025293 109/2618 
GO:0010632# regulation of epithelial cell migration 0.001277 0.022584 27/1114 
GO:0001890 placenta development 0.001241 0.024771 44/2618 
GO:0000075 cell cycle checkpoint 0.001226 0.024573 65/2618 
GO:0050878*# regulation of body fluid levels 0.001202 0.021794 55/1114 
GO:0048871*# multicellular organismal homeostasis 0.001145 0.02338 74/2618 
GO:0060688 regulation of morphogenesis of a branching 
structure 
0.001142 0.021153 12/1114 
GO:0030278 regulation of ossification 0.001126 0.021135 28/1114 
GO:0021700 developmental maturation 0.001126 0.021135 30/1114 
GO:0007420 brain development 0.001023 0.019793 68/1114 
GO:0034975 protein folding in endoplasmic reticulum 0.000932 0.018367 6/1114 
GO:0045787 positive regulation of cell cycle 0.000877 0.019799 84/2618 
GO:0007588# excretion 0.000831 0.01932 17/2618 
GO:0060322 head development 0.000711 0.014806 72/1114 
GO:0000910 cytokinesis 0.000688 0.01461 22/1114 
GO:0009991# response to extracellular stimulus 0.000663 0.016943 104/2618 
GO:1900182 positive regulation of protein localization to 
nucleus 
0.000624 0.01373 23/1114 
GO:0007051 spindle organization 0.000573 0.012792 20/1114 
GO:0035295*# tube development 0.000472 0.011122 70/1114 
GO:0010035*# response to inorganic substance 0.000451 0.01071 58/1114 
GO:0010817 regulation of hormone levels 0.000417 0.012929 101/2618 
GO:0007565*# female pregnancy 0.000392 0.009534 26/1114 
GO:0009612# response to mechanical stimulus 0.000381 0.009329 29/1114 
GO:0007059 chromosome segregation 0.000374 0.009253 46/1114 
GO:0071674*# mononuclear cell migration 0.000356 0.008929 16/1114 
GO:0009617*# response to bacterium 0.000347 0.008841 58/1114 
GO:0051965 positive regulation of synapse assembly 0.000338 0.01115 15/2618 
GO:0031099 regeneration 0.000334 0.008614 26/1114 
GO:0051963 regulation of synapse assembly 0.000329 0.011127 19/2618 
GO:2000241# regulation of reproductive process 0.00032 0.008348 20/1114 
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GO:0048608 reproductive structure development 0.000304 0.010693 103/2618 
GO:1904951*# positive regulation of establishment of protein 
localization 
0.000261 0.009705 127/2618 
GO:0044770 cell cycle phase transition 0.000251 0.006939 65/1114 
GO:0033628 regulation of cell adhesion mediated by integrin 0.000251 0.006939 12/1114 
GO:0007568# aging 0.000246 0.006875 39/1114 
GO:0019953 sexual reproduction 0.000203 0.005876 64/1114 
GO:0044246# regulation of multicellular organismal metabolic 
process 
0.000199 0.005779 10/1114 
GO:0044253*# positive regulation of multicellular organismal 
metabolic process 
0.000194 0.005722 7/1114 
GO:0009636 response to toxic substance 0.000191 0.007633 60/2618 
GO:1904018*# positive regulation of vasculature development 0.000186 0.005722 25/1114 
GO:0032206 positive regulation of telomere maintenance 0.000156 0.005189 13/1114 
GO:0001556 oocyte maturation 0.000153 0.005127 8/1114 
GO:0006805 xenobiotic metabolic process 0.000147 0.006524 28/2618 
GO:0007586*# digestion 0.000146 0.006524 39/2618 
GO:0042493*# response to drug 0.000143 0.004907 54/1114 
GO:0003006 developmental process involved in reproduction 0.000136 0.004732 69/1114 
GO:0006403 RNA localization 0.000133 0.049701 77/3344 
GO:0090130*# tissue migration 0.00013 0.004593 38/1114 
GO:0051301 cell division 0.000126 0.004554 74/1114 
GO:2000242*# negative regulation of reproductive process 0.000122 0.004503 12/1114 
GO:0009410 response to xenobiotic stimulus 0.000121 0.005947 31/2618 
GO:0008285*# negative regulation of cell proliferation 0.00011 0.004097 80/1114 
GO:0019725*# cellular homeostasis 0.000109 0.004097 86/1114 
GO:0098813 nuclear chromosome segregation 0.000102 0.003929 42/1114 
GO:0006959*# humoral immune response 9.94E-05 0.005421 44/2618 
GO:0032844*# regulation of homeostatic process 7.79E-05 0.003201 57/1114 
GO:0032101*# regulation of response to external stimulus 7.78E-05 0.003201 82/1114 
GO:0045785*# positive regulation of cell adhesion 6.15E-05 0.002718 54/1114 
GO:0001763*# morphogenesis of a branching structure 5.68E-05 0.002591 34/1114 
GO:0032846* positive regulation of homeostatic process 5.37E-05 0.002475 33/1114 
GO:0001666*# response to hypoxia 4.79E-05 0.002282 44/1114 
GO:1904872 regulation of telomerase RNA localization to 
Cajal body 
3.84E-05 0.00189 8/1114 
GO:1904874 positive regulation of telomerase RNA 
localization to Cajal body 
3.84E-05 0.00189 8/1114 
GO:0048729*# tissue morphogenesis 3.12E-05 0.001746 80/1114 
GO:0006520 cellular amino acid metabolic process 2.90E-05 0.001654 47/1114 
GO:0040008# regulation of growth 2.67E-05 0.002058 149/2618 
GO:0032204 regulation of telomere maintenance 2.33E-05 0.001382 17/1114 
GO:0010564 regulation of cell cycle process 2.25E-05 0.001376 75/1114 
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GO:0070482*# response to oxygen levels 1.98E-05 0.001242 48/1114 
GO:0042330*# taxis 1.79E-05 0.001198 71/1114 
GO:0006935*# chemotaxis 1.62E-05 0.001153 71/1114 
GO:0009611*# response to wounding 1.46E-05 0.001069 81/1114 
GO:0010942# positive regulation of cell death 1.33E-05 0.000992 81/1114 
GO:0001704# formation of primary germ layer 1.04E-05 0.000805 25/1114 
GO:0002687*# positive regulation of leukocyte migration 1.04E-05 0.000805 26/1114 
GO:0032103*# positive regulation of response to external 
stimulus 
1.01E-05 0.000805 43/1114 
GO:0050673*# epithelial cell proliferation 9.29E-06 0.000775 52/1114 
GO:0097529*# myeloid leukocyte migration 8.82E-06 0.000749 31/1114 
GO:0050920*# regulation of chemotaxis 7.32E-06 0.000634 34/1114 
GO:0050921*# positive regulation of chemotaxis 5.16E-06 0.000497 27/1114 
GO:0031589* cell-substrate adhesion 2.66E-06 0.000311 51/1114 
GO:0051093*# negative regulation of developmental process 2.61E-06 0.000311 95/1114 
GO:0030155*# regulation of cell adhesion 1.90E-06 0.000245 89/1114 
GO:0006956*# complement activation 1.19E-06 0.000232 26/2618 
GO:0040013*# negative regulation of locomotion 1.03E-06 0.00014 45/1114 
GO:0044703# multi-organism reproductive process 8.78E-07 0.000123 88/1114 
GO:0030595*# leukocyte chemotaxis 6.79E-07 9.80E-05 38/1114 
GO:2000146*# negative regulation of cell motility 5.01E-07 7.48E-05 43/1114 
GO:0001101*# response to acid chemical 4.75E-07 7.48E-05 46/1114 
GO:0051271*# negative regulation of cellular component 
movement 
4.75E-07 7.48E-05 46/1114 
GO:0033627*# cell adhesion mediated by integrin 3.19E-07 5.54E-05 19/1114 
GO:0010243*# response to organonitrogen compound 3.14E-07 5.54E-05 97/1114 
GO:0040017*# positive regulation of locomotion 2.33E-07 4.40E-05 69/1114 
GO:2000147*# positive regulation of cell motility 1.36E-07 2.81E-05 69/1114 
GO:0001503# ossification 1.35E-07 2.81E-05 59/1114 
GO:0002685# regulation of leukocyte migration 9.66E-08 2.20E-05 36/1114 
GO:0051272# positive regulation of cellular component 
movement 
7.07E-08 1.80E-05 71/1114 
GO:0001525*# angiogenesis 1.72E-09 5.34E-07 75/1114 
GO:0048514*# blood vessel morphogenesis 1.54E-09 5.13E-07 84/1114 
GO:0022613 ribonucleoprotein complex biogenesis 6.57E-10 2.95E-06 181/3344 
GO:0001568*# blood vessel development 3.62E-12 1.96E-09 101/1114 
GO:0044236*# multicellular organism metabolic process 9.69E-13 7.00E-10 38/1114 
GO:0043062*# extracellular structure organization 3.57E-21 7.75E-18 85/1114 
Note: * indicates shared pathways with CD; # indicates shared pathways with UC;  
 
